TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33637058

Group type: EXPERIMENTAL
Intervention: Digital handle
Number of subjects: 567

Group type: COMPARATOR
Intervention: Conventional handle
Number of subjects: 567
Study: 32665040

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 2440

Group type: EXPERIMENTAL
Intervention: Lopinavir (400mg) / Ritonavir (100mg) twice daily for 10 days
Number of subjects: 2440

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (800mg on Day 1, followed by 400mg twice a day for 6 days)
Number of subjects: 2440

Group type: EXPERIMENTAL
Intervention: Lopinavir / Ritonavir plus Hydroxychloroquine
Number of subjects: 2440
Study: 36501136

Group type: EXPERIMENTAL
Intervention: Extra-Virgin Olive Oil (EVOO)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Refined Olive Oil (ROO)
Number of subjects: 26

Group type: COMPARATOR
Intervention: EVOO and ROO
Number of subjects: 26
Study: 33628403

Group type: EXPERIMENTAL
Intervention: Lower limb joint nursing and rehabilitation system based on intelligent medical treatment
Number of subjects: 55
Study: 33382931

Group type: EXPERIMENTAL
Intervention: Higher hemoglobin threshold for red-cell transfusion
Number of subjects: 1824

Group type: COMPARATOR
Intervention: Lower hemoglobin threshold for red-cell transfusion
Number of subjects: 1824
Study: 34075872

Group type: EXPERIMENTAL
Intervention: Antibiotic prescribing for respiratory tract diagnoses (RTDs)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Metrics utilizing prespecified RTDs
Number of subjects: 1200

Group type: COMPARATOR
Intervention: APP versus physician
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Family medicine versus internal medicine
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Board certification 1997 or later versus before 1997
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Nonteaching versus teaching practice
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Nonurban versus urban practice
Number of subjects: 1200
Study: 33988948

Group type: EXPERIMENTAL
Intervention: PKP + FJB
Number of subjects: 194

Group type: COMPARATOR
Intervention: PKP
Number of subjects: 194
Study: 34038624

Group type: EXPERIMENTAL
Intervention: Leisure walking
Number of subjects: 66

Group type: COMPARATOR
Intervention: Self-chosen activity at home (Control)
Number of subjects: 66
Study: 32881712

Group type: EXPERIMENTAL
Intervention: Low back stretch
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Wrist stretch
Number of subjects: 22
Study: 33493833

Group type: EXPERIMENTAL
Intervention: Syndecan-1 levels at baseline (T0)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Syndecan-1 levels at T0 and T6
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Syndecan-1 levels at T6
Number of subjects: 95
Study: 32473959

Group type: EXPERIMENTAL
Intervention: Personalised cancer risk information (bar chart, pictograph, qualitative scale) alongside cancer-specific lifestyle advice
Number of subjects: 1018

Group type: COMPARATOR
Intervention: Control group receiving cancer-specific lifestyle advice
Number of subjects: 1018
Study: 35636341

Group type: COMPARATOR
Intervention: TP (Trastuzumab and Pertuzumab)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: TPM (metronomic oral cyclophosphamide + Trastuzumab + Pertuzumab)
Number of subjects: 80

Group type: COMPARATOR
Intervention: TP
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: TPM
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: T-DM1 after progression
Number of subjects: 80
Study: 32710584

Group type: EXPERIMENTAL
Intervention: Porcine Dermis (PD)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Polynucleotides-added Hyaluronic Acid (PAHA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Polyurethane Foam (Control)
Number of subjects: 30
Study: 34844756

Group type: EXPERIMENTAL
Intervention: Inflammatory markers (IL‐1ra, IL‐6, IL‐8, IL‐10, eotaxin, IP‐10, MCP‐1) measured at various time points (2, 12, 24, and 72 hours)
Number of subjects: 680
Study: 33704540

Group type: EXPERIMENTAL
Intervention: 60 SWs/min
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 90 SWs/min
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 120 SWs/min
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Low frequency (60 SWs/min) may be more advantageous than intermediate (90 SWs/min) due to lower number of high energy shock waves causing less tissue damage; longer anesthesia time may be a disadvantage.
Number of subjects: 75
Study: 35532113

Group type: EXPERIMENTAL
Intervention: Custom mandibular advancement device (MAD) applied for 12 weeks
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Non-custom mandibular advancement device (MAD) applied for 12 weeks
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Self-reported outcomes for both custom and non-custom MADs
Number of subjects: 58
Study: 33750355

Group type: EXPERIMENTAL
Intervention: Folic Acid (FA) supplementation 400 μg/day from the 14th gestational week
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 32006633

Group type: EXPERIMENTAL
Intervention: Technology delivered activity breaks (PAAC-R)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Classroom teacher delivered activity breaks (PAAC-T)
Number of subjects: 0
Study: 35051669

Group type: EXPERIMENTAL
Intervention: Manual fetal stimulation (abdominal stimulation when cervical dilatation <3 cm or vaginal stimulation when cervical dilatation ≥3 cm)
Number of subjects: 327

Group type: COMPARATOR
Intervention: No stimulation
Number of subjects: 327
Study: 34284778

Group type: EXPERIMENTAL
Intervention: Incidence of malaria infections
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Incidence of malaria
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Incidence of first malaria
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Incidence of first malaria in 6–59-month-olds
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Incidence of first malaria in 5–17-year-olds
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Incidence of first malaria in 18–45-year-olds
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Incidence of first malaria with symptoms
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Incidence of first malaria with symptoms in 6–59-month-olds
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Incidence of first malaria with symptoms in 5–17-year-olds
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Incidence of first malaria with symptoms in 18–45-year-olds
Number of subjects: 240
Study: 35351553

Group type: EXPERIMENTAL
Intervention: Exparel
Number of subjects: 100
Study: 34185013

Group type: EXPERIMENTAL
Intervention: SWAP IT intervention
Number of subjects: 3022

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 3022
Study: 32115759

Group type: EXPERIMENTAL
Intervention: cilofexor 100 mg
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: cilofexor 30 mg
Number of subjects: 140

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 140
Study: 33037255

Group type: EXPERIMENTAL
Intervention: Eyelid warming steamer (EWS) for 2 weeks
Number of subjects: 45
Study: 34032286

Group type: EXPERIMENTAL
Intervention: Continuous infusion of rEPO (loading dose 2000 IU, infusion at 520 IU/h) from 6 to 72 h post-asphyxia
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intermittent rEPO boluses started 6 h after asphyxia
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intravenous saline or 5000 IU rEPO, with repeated doses every 48 h for 5 days
Number of subjects: 8
Study: 32383503

Group type: EXPERIMENTAL
Intervention: Standard face‐to‐face CBT plus mobile intervention (TCApp)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard face‐to‐face CBT only
Number of subjects: 106
Study: 35778620

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) treatment for 7 days
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) treatment
Number of subjects: 89
Study: 33212205

Group type: EXPERIMENTAL
Intervention: Multicomponent behavioral intervention program including fluid intake prescription and adaptive behavioral interventions (financial incentives, structured problem solving, automated adherence interventions)
Number of subjects: 1642

Group type: COMPARATOR
Intervention: Guideline-based fluid instructions
Number of subjects: 1642
Study: 33028243

Group type: EXPERIMENTAL
Intervention: Integrated GP care plus treatment as usual
Number of subjects: 161

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 161
Study: 35398241

Group type: EXPERIMENTAL
Intervention: 3 mg/kg/day Zataria multiflora extract
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 6 mg/kg/day Zataria multiflora extract
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 34486305

Group type: EXPERIMENTAL
Intervention: KCl 0.45 g/polybag + T. asperellum 30 g/polybag (K3)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: KCl 0.15 g/polybag + T. asperellum 50 g/polybag (K1)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: KCl 0.30 g/polybag + T. asperellum 40 g/polybag (K2)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: KCl 0.60 g/polybag + T. asperellum 20 g/polybag (K4)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: KCl 0.75 g/polybag + T. asperellum 10 g/polybag (K5)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Without KCl fertilizer and T. asperellum (K0)
Number of subjects: 4
Study: 35447154

Group type: EXPERIMENTAL
Intervention: Gigiigoo'inaan software intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 35179312

Group type: EXPERIMENTAL
Intervention: MADS technique
Number of subjects: 143
Study: 35730664

Group type: EXPERIMENTAL
Intervention: Oral methotrexate (MTX) at a full dose of 0.3 mg/kg/week (maximum 25 mg/week) for 12 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Subcutaneous methotrexate (MTX) at a full dose of 0.3 mg/kg/week (maximum 25 mg/week) for 12 weeks
Number of subjects: 100
Study: 34147090

Group type: EXPERIMENTAL
Intervention: Serum NT-proBNP levels on day 2-3 of life
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Serum NT-proBNP levels on day 8-9 of life
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Treatment of infants with hemodynamically significant PDA (hsPDA)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Detection of hsPDA
Number of subjects: 52
Study: 32167494

Group type: EXPERIMENTAL
Intervention: Femoral central venous catheter insertion site
Number of subjects: 7235

Group type: COMPARATOR
Intervention: Nonfemoral central venous catheter insertion site
Number of subjects: 7235

Group type: EXPERIMENTAL
Intervention: Femoral arterial catheter insertion site
Number of subjects: 7235

Group type: COMPARATOR
Intervention: Radial arterial catheter insertion site
Number of subjects: 7235
Study: 32915000

Group type: EXPERIMENTAL
Intervention: Randomized response models (RRMs) with curtailed sampling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Curtailed sampling
Number of subjects: 0
Study: 36093907

Group type: EXPERIMENTAL
Intervention: L-arginine (8 g/d for 7 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (7 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 8
Study: 32856181

Group type: EXPERIMENTAL
Intervention: Plate osteosynthesis with additional wire cerclage
Number of subjects: 16

Group type: COMPARATOR
Intervention: Plate osteosynthesis without additional wire cerclage (control)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups (comparison)
Number of subjects: 16
Study: 36096651

Group type: EXPERIMENTAL
Intervention: Ballroom dance (n = 23)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Music (ukulele-playing, n = 17)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Social conversation (n = 24)
Number of subjects: 64
Study: 34342026

Group type: EXPERIMENTAL
Intervention: Adaptive left ventricular‐only fusion pacing (LVP)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Conventional biventricular pacing (BVP)
Number of subjects: 63
Study: 33618033

Group type: EXPERIMENTAL
Intervention: Fibromyalgia Integrative Training program for Teens (FIT Teens)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Graded aerobic exercise (GAE)
Number of subjects: 420
Study: 34174970

Group type: EXPERIMENTAL
Intervention: Low dose aspirin
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 393

Group type: COMPARATOR
Intervention: Control (drug-free)
Number of subjects: 393
Study: 36103181

Group type: EXPERIMENTAL
Intervention: Minocycline (200 mg/d)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study: 34034790

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 40
Study: 32792102

Group type: EXPERIMENTAL
Intervention: Structured diabetes education
Number of subjects: 3
Study: 35694030

Group type: EXPERIMENTAL
Intervention: Curcumin (4000 mg daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 34524394

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan for 3 years
Number of subjects: 4682098
Study: 34034690

Group type: EXPERIMENTAL
Intervention: ADVANCE intervention + substance use treatment as usual (TAU), n=54
Number of subjects: 104

Group type: COMPARATOR
Intervention: TAU only, n=50
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: ADVANCE intervention
Number of subjects: 104
Study: 616191660

Group type: EXPERIMENTAL
Intervention: Seated AECT
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Supine AECT
Number of subjects: 18

Group type: COMPARATOR
Intervention: Compression Therapy (CT)
Number of subjects: 18
Study: 33478480

Group type: EXPERIMENTAL
Intervention: Erythritol air-polishing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional ultrasonic/curette debridement
Number of subjects: 20
Study: 33960119

Group type: EXPERIMENTAL
Intervention: mirabegron 50 mg QD
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: solifenacin 5 mg QD
Number of subjects: 90

Group type: COMPARATOR
Intervention: onabotulinumtoxinA only
Number of subjects: 90
Study: 34519141

Group type: EXPERIMENTAL
Intervention: Aerolizer® with 200 µg salbutamol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Handihaler® with 200 µg salbutamol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Optimal PIFR
Number of subjects: 20

Group type: COMPARATOR
Intervention: Suboptimal PIFR
Number of subjects: 20
Study: 32454458

Group type: EXPERIMENTAL
Intervention: 10-week after-school physical activity (PA) program
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sedentary attention control
Number of subjects: 35
Study: 33948712

Group type: EXPERIMENTAL
Intervention: Lenvatinib (8 mg/day for < 60 kg; 12 mg/day for ≥ 60 kg)
Number of subjects: 951

Group type: EXPERIMENTAL
Intervention: Lenvatinib
Number of subjects: 951

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 951
Study: 36047646

Group type: EXPERIMENTAL
Intervention: STRATIFY + POCecho variable
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: TAPSE ≥ 17 mm plus STRATIFY
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Five right heart measures (TAPSE, TAPSE/PASP, TAPSE/RVDD, RV-FAC, fwRVLS)
Number of subjects: 84

Group type: COMPARATOR
Intervention: STRATIFY alone
Number of subjects: 84
Study: 34780022

Group type: EXPERIMENTAL
Intervention: SGLT-2 inhibitors (dapagliflozin 10 mg or empagliflozin 10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Guideline-directed medical therapy
Number of subjects: 0
Study: 34479930

Group type: EXPERIMENTAL
Intervention: Retrorectus mesh augmentation with lightweight polypropylene mesh
Number of subjects: 470

Group type: COMPARATOR
Intervention: Primary suture closure
Number of subjects: 470
Study: 32496349

Group type: EXPERIMENTAL
Intervention: Nomogram model based on independent prognostic factors (age, sex, T stage, N stage, bone metastasis) for predicting overall survival (OS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nomogram model for predicting 3-year OS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nomogram model for predicting 5-year OS
Number of subjects: 0
Study: 36151932

Group type: EXPERIMENTAL
Intervention: 4-implant group
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 6-implant group
Number of subjects: 66

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 66
Study: 32165547

Group type: EXPERIMENTAL
Intervention: Patients who had a stroke
Number of subjects: 7550

Group type: COMPARATOR
Intervention: Patients who had not had a stroke (control group)
Number of subjects: 7550

Group type: EXPERIMENTAL
Intervention: Stroke history
Number of subjects: 7550
Study: 36114552

Group type: EXPERIMENTAL
Intervention: Remimazolam besylate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 60
Study: 33461488

Group type: EXPERIMENTAL
Intervention: Individual factors (including physical, mental, and social characteristics)
Number of subjects: 3500

Group type: EXPERIMENTAL
Intervention: Environmental factors (including social and material environment)
Number of subjects: 3500
Study: 33033088

Group type: EXPERIMENTAL
Intervention: Progressive walking and education programme
Number of subjects: 349

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 349
Study: 33357008

Group type: EXPERIMENTAL
Intervention: Energy-deficit (ED) diet (1590 ± 79 kcal day‐1: 40% of total caloric omitted at lunchtime) with high-intensity cycling at 90% V˙O2peak
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (CON) group (2570 ± 139 kcal day‐1) with high-intensity cycling at 90% V˙O2peak
Number of subjects: 20
Study: 35343449

Group type: EXPERIMENTAL
Intervention: PEKK double crown-retained RPDs
Number of subjects: 18

Group type: COMPARATOR
Intervention: PEEK double crown-retained RPDs
Number of subjects: 18
Study: 32343422

Group type: EXPERIMENTAL
Intervention: Personalised, structured, video-enhanced feedback and deliberate practice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (experienced prescribers)
Number of subjects: 0
Study: 33092415

Group type: EXPERIMENTAL
Intervention: Progestin-primed ovarian stimulation (PPOS)
Number of subjects: 63

Group type: COMPARATOR
Intervention: GnRH antagonist (GnRH-A)
Number of subjects: 63
Study: 34604251

Group type: EXPERIMENTAL
Intervention: Huashibaidu granule 10 g twice daily
Number of subjects: 408

Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 408
Study: 34791324

Group type: EXPERIMENTAL
Intervention: PCV-10
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: PPV-23
Number of subjects: 346

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Postpartum vaccination
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Antepartum vaccination
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Postvaccination factors
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Serotype 1 B- and T-cell memory
Number of subjects: 346
Study: 33337109

Group type: EXPERIMENTAL
Intervention: Conventional energy drink (ED1) containing carbohydrates and 3 mg·kg‐1 of caffeine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sugar-free energy drink (ED2) containing 3 mg·kg‐1 of caffeine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PL) - carbohydrate-containing, decaffeinated
Number of subjects: 12
Study: 36181010

Group type: EXPERIMENTAL
Intervention: Codonopsis lanceolata water extract for 12 weeks
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 104
Study: 33418103

Group type: EXPERIMENTAL
Intervention: Prophylactic manual rotation
Number of subjects: 254

Group type: COMPARATOR
Intervention: Sham rotation
Number of subjects: 254
Study: 32429429

Group type: EXPERIMENTAL
Intervention: Cod residual protein (Cod-RP) 8.1 g/day for eight weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (Control group)
Number of subjects: 50
Study: 33856613

Group type: EXPERIMENTAL
Intervention: Intranasal insulin (0-120 IU of NovoLog) with exercise
Number of subjects: 116

Group type: COMPARATOR
Intervention: Intranasal insulin (0-120 IU of NovoLog) with sitting control
Number of subjects: 116
Study: 36428075

Group type: EXPERIMENTAL
Intervention: Psychoeducation based on the Transtheoretical Model (6-week program, 6 modules)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Psychoeducation based on the Transtheoretical Model
Number of subjects: 82
Study: 32591295

Group type: EXPERIMENTAL
Intervention: HF nurse titration
Number of subjects: 320

Group type: COMPARATOR
Intervention: HF cardiologist titration
Number of subjects: 320
Study: 32307307

Group type: EXPERIMENTAL
Intervention: DTaP-IPV/Hib (Group A)
Number of subjects: 424

Group type: COMPARATOR
Intervention: DTaP-IPV + Hib (Group B)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: DTaP-IPV/Hib (Group C, IM route)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: DTaP-IPV/Hib (Group A, Group C)
Number of subjects: 424
Study: 36017158

Group type: EXPERIMENTAL
Intervention: LCPT
Number of subjects: 401

Group type: COMPARATOR
Intervention: IR-Tac/PR-Tac
Number of subjects: 401
Study: 32854056

Group type: EXPERIMENTAL
Intervention: Poly-victimization
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Poly-deprivation
Number of subjects: 100
Study: 34533193

Group type: EXPERIMENTAL
Intervention: 3U botulinum toxin type A injected at dilator naris anterior, dilator naris vestibularis, levator labii superioris alaeque nasi, and dilator naris
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 3U botulinum toxin type A
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Root mean square analysis
Number of subjects: 20
Study: 32894967

Group type: EXPERIMENTAL
Intervention: Polypill (hydrochlorothiazide 12.5 mg, aspirin 81 mg, atorvastatin 20 mg, and either enalapril 5 mg or valsartan 40 mg)
Number of subjects: 4415

Group type: COMPARATOR
Intervention: Minimal non-pharmacological care (control)
Number of subjects: 4415
Study: 32569090

Group type: EXPERIMENTAL
Intervention: Intrathecal hydromorphone (ITHM)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Intrathecal morphine (ITMO)
Number of subjects: 233
Study: 34843940

Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg/body) administered every 2 weeks for up to 52 cycles
Number of subjects: 56
Study: 34388561

Group type: EXPERIMENTAL
Intervention: SSRIs with acupuncture
Number of subjects: 112

Group type: COMPARATOR
Intervention: SSRIs with sham acupuncture (control group)
Number of subjects: 112

Group type: COMPARATOR
Intervention: SSRIs alone (drug group)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 112